Qi Deng
Clinical trials sponsored by Qi Deng, explained in plain language.
-
New CAR-T therapy targets Hard-to-Treat blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new type of CAR-T cell therapy (GPRC5D) in 18 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The goal is to see if the therapy is safe and can shrink or control the cancer. Researchers wil…
Phase: EARLY_PHASE1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Not yet recruitingThis early-phase study tests a new type of CAR-T cell therapy (FO33 CAR-T) for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target a protein called CD33 found on mos…
Phase: PHASE1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New drug combo aims to tame stubborn blood disorders
Disease control Not yet recruitingThis early-phase study tests whether combining two drugs (Zuberitamab and Orelabrutinib) can help people with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA) that hasn't responded to other treatments. The drugs work together to calm the immune system and stop …
Phase: PHASE1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New CAR-T shot could slash cancer treatment costs and time
Disease control Not yet recruitingThis early-phase study tests a new type of CAR-T cell therapy that works inside the body, avoiding the complex and costly lab process usually needed. It targets two markers (CD19 and BAFF-R) on cancer cells in people with relapsed or hard-to-treat B-cell leukemia or lymphoma. The…
Phase: PHASE1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC